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ABSTRACT
Background Hematological parameters like red cell 
distribution width (RDW) and mean platelet volume 
(MPV) were reported to be associated with inflamma-
tion, atherosclerosis, and chronic kidney disease (CKD) 
progression. In this study, we evaluated RDW and MPV 
along with clinical features in patients with advanced 
CKD. We also aimed to detect clues for causative rela-
tions concerning these parameters, renal function and 
comorbidities.
Methods Stage 3-5 CKD patients (627 total) were in-
cluded (mean age 63.1 years, 48.3% male). Patients with 
malignancies, cirrhosis, infections, severe anemia, and 
systemic inflammation were excluded. Patients were 
evaluated for clinical features and grouped for compari-
son using median RDW and MPV. Linear regression 
models were generated to predict potential influences on 
RDW and MPV.
Results Mean estimated glomerular filtration rate 
(eGFR) was 27.3 mL/min/1.73m2. Mean Charlson 
Comorbidity Index (CCI) score was 5.83 ± 2.06. Patients 
with high RDW (n = 303) were older with higher CRP 
and CCI, they also had lower eGFR, hemoglobin, and 
albumin (P < 0.001 for all). Patients with low MPV (n 
= 311) had lower eGFR, and platelet counts (P = 0.015 
and 0.017). eGFR was negatively correlated with RDW 
after adjusting for age, gender and comorbidities. In a 
further adjusted model RDW was associated with CRP, 
CCI, hemoglobin and albumin (P < 0.05 for all), not 
with eGFR. MPV was positively correlated with eGFR 
in our adjusted, and fully adjusted regression models (P 
= 0.003).
Conclusion In this study, we found that high RDW 
is associated with comorbidity burden, anemia, and 
inflammatory status in patients with advanced CKD. 
Meanwhile, low MPV seems to be associated with 
worse renal function.
Key words blood platelets; chronic kidney failure; 
erythrocyte indices; mean platelet volume; red cell dis-
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Chronic kidney disease (CKD) is considered as an 
inflammatory state leading to atherosclerosis, metabolic 
abnormalities, and accelerated aging. Hematological 
parameters like red cell distribution width (RDW), and 
mean platelet volume (MPV) have been reported as 
measures of chronic inflammation, cardiovascular dis-
ease (CVD), anemia, and worse renal outcome, in CKD 
patients.1, 2 Therefore, it could be wise to use them as 
follow-up markers for some of our patients with CKD.
RDW measures the size variation of the circulating 
erythrocytes. Increased size variability of the erythro-
cytes is defined as anisocytosis, and demonstrated as 
high RDW values on blood count readings.3 High RDW 
was found to be associated with adverse renal outcome, 
CVD, and mortality in patients with CKD.1, 3, 4
MPV is a test that measures the size of the circu-
lating platelets. Large platelets are generally younger 
with more reactive granules to induce adhesion and 
aggregation. Therefore, increased MPV was introduced 
as an indicator of platelet reactivity, atherosclerosis, and 
inflammatory status.2, 5 On the other hand, patients with 
severe inflammation and some patients with advanced 
CKD have been reported to have low MPV levels.6, 7
In the routine follow-up of patients with advanced 
CKD, we monitor them for complications like anemia, 
phosphorus retention, metabolic acidosis and loss of 
glomerular filtration. On the other hand, we do not have 
numeric follow-up markers that provide information 
about their inflammatory status and susceptibility to 
these disease related complications. Using markers of 
everyday clinical practice like RDW and MPV for this 
purpose could be quite advantageous. Yet, it is not clear 
which clinical outcomes are predominantly associated 
with hematological parameters in CKD patients. New 
studies could make it possible to integrate RDW and 
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MPV in the follow-up of CKD patients.
In this study, we evaluated these hematological 
parameters along with clinical features in patients with 
advanced CKD. We also aimed to detect some clues 
for causative relations concerning these hematological 
parameters, renal function and comorbidity.
MATERIALS AND METHODS
Recruitment and data collection
Our retrospective, cross-sectional study included 627 
patients with stage 3-5 CKD who admitted to our hospi-
tal in the last 2 years (366 male, 261 female; mean age: 
63.18 ± 14.94 years). Exclusion criteria were; patients 
younger than 18 years of age, patients with missing 
data, patients with a diagnosis of malignant disease, 
liver cirrhosis, congestive heart failure, thyroid dysfunc-
tion, those with active infection, having the diagnosis of 
hematologic diseases, and/or severe anemia (hemoglobin 
< 8gr/dL), active systemic inflammatory conditions, and 
having corticosteroid therapy.
Laboratory values were obtained from the data 
bank. Patients were divided into CKD stages using their 
estimated glomerular filtration rates (eGFR) calculated 
by MDRD (Modification of Diet in Renal Disease) for-
mulation.8 For HD patients we selected the laboratory 
data of their mid-week pre-dialytic values. Accordingly, 
280 patients were in stage 3, 172 in stage 4, and 175 
were in stage 5 (86 in maintenance hemodialysis, 18 
in chronic peritoneal dialysis) CKD. The comorbidity 
scores of our CKD patients were calculated using the 
Charlson Comorbidity Index (CCI).9 CVD was defined 
as the history of cardiac and/or peripheral vascular 
disease, and hypertension was defined as the use of one 
or more anti-hypertensive drugs. The reference range 
values for RDW and MPV in our laboratory were 11.5-
14.5%, and 7-11 fl respectively. CKD patients were also 
grouped for comparison using the median values for 
RDW, and MPV. The study was approved by the insti-
tutional ethics review board (IRB number: 2019/18-10), 
and conducted between October and December of 2019.
Statistical analysis
We analyzed the data using SPSS software, version 19.0 
(IBM Corp., Armonk, NY). Values were expressed as 
mean ± standard deviation or percentages. Any P value 
less than 0.05 were accepted as statistically significant. 
Categorical data were compared using chi-square test or 
Fisher’s exact test. Shapiro-Wilk test was used to check 
the normality of distribution for continuous variables. 
Differences between continuous variables were com-
pared by the Student’s t-test and the Mann Whitney-U 
test. Pearson’s and Spearman’s tests were used for 
correlation analysis. Multiple comparisons of RDW and 
MPV were conducted by Tukey’s test. We generated 
linear regression models with Enter method to predict 
the potential influences on RDW and MPV. The first 
model was used to show the effect of eGFR on RDW 
and MPV. The second model included adjustments for 
demogrraphics and comorbid conditions, and the final 
model was designed to reveal the influences of various 
confounders on hematological parameters.
RESULTS
Hematological parameters and clinical data
The mean RDW was 14.79 ± 1.99, and the mean MPV 
was 9.73 ± 1.55 in our patients with stage 3-5 CKD. 
The number of patients with the diagnosis of diabetes 
mellitus (DM) and coronary artery disease (CAD) were 
291 (46.4%) and 242 (38.6%), respectively. The mean 
CCI score was 5.83 ± 2.06. The mean hemoglobin and 
platelet values were 12.02 ± 2.21 g/dL, and 238.49 ± 
79.20 x103/mm3, respectively. Demographics, clinical 
features, and laboratory values within the study popula-
tion is presented in Table 1.
Comparison of hematological parameters and clin-
ical data
In our study stage 3-5 CKD patients with RDW above 
the median value (14.5%) were older with increased 
frequencies for DM and CVD. They had lesser male 
gender predominancy, lower mean eGFR, albumin, and 
hemoglobin values, but higher mean CCI scores and 
CRP values. On the contrary, patients with MPV below 
the median value (9.9 fl) had lower mean eGFR, higher 
serum creatinine levels, and higher platelet counts (P < 
0.05 for all, Table 2).
RDW was negatively correlated with eGFR, 
albumin, and hemoglobin levels, it was also positively 
correlated with patient age, CCI score, and CRP levels 
in our patients with advanced CKD. On the other hand, 
MPV was positively correlated with eGFR, albumin, 
and hemoglobin levels, it was also negatively correlated 
with CRP levels and platelet count (P < 0.05 for all, 
Table 3).
CKD patients with a diagnosis of CAD had higher 
RDW levels (15.21 ± 2.17 > 14.52 ± 1.82, P < 0.001). 
Mean MPV was not different for CKD patients with a 
diagnosis of CAD compared with those without CAD 
(9.70 ± 1.71 vs 9.75 ± 1.44, P = 0.732). Multiple com-
parisons of RDW and MPV according to CKD stages 
revealed some significant differences. RDW was signifi-
cantly higher in patients with stage 5 CKD compared to 
patients with stage 3 CKD (15.14 ± 1.85 vs 14.62 ± 2.00, 
P = 0.017), but not to those with stage 4 CKD (15.14 ± 1.85 
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vs 14.71 ± 2.07, P = 0.109). MPV was significantly lower 
in patients with stage 5 CKD compared to patients with 
stage 3 and stage 4 CKD (9.34 ± 1.53 vs 9.88 ± 1.39, P 
= 0.001), (9.34 ± 1.53 vs 9.88 ± 1.74, P = 0.003), respec-
tively (Fig. 1).
We used a stepwise linear regression analysis 
model for eGFR and other potential influences on RDW 
and MPV. In the first adjusted model (controlled for age, 
gender, DM, CVD, and HT), both RDW and MPV were 
still associated with eGFR. In a further adjusted model 
controlled for multiple possible confounders, RDW was 
not associated with eGFR, but it was associated with 
CCI score, CRP, albumin, and hemoglobin values. On 
the other hand, MPV was associated with eGFR and the 
platelet count in the fully adjusted regression model (P 
< 0.05 for all, Table 4).
DISCUSSION
Recent studies indicated some relations between routine 
hematological parameters and adverse clinical outcomes 
in patients with CKD.2, 4, 10, 11 New studies might help 
to find the causality of such relations, whether they are 
predominantly associated with renal anemia, chronic 
inflammation or residual renal function.
CKD is a condition that leads to anemia, endothe-
lial dysfunction, systemic inflammation, malnutrition, 
and accelerated atherosclerosis. Altogether, these condi-
tions may affect the maturation of erythroid cell lines 
due to microvascular hypoxia and chronic cytokine 
exposure in the bone marrow.1, 11, 12 Therefore, it is 
probable that patients with advanced CKD would have 
elevated RDW. Platelets that are larger and more reac-
tive may increase the tendency to vascular thrombosis 
in patients with CKD who usually have an unhealthy 
endothelium. MPV is usually increased in chronic in-
flammatory conditions including CKD, but the opposite 
is also possible in severe inflammatory status.5, 7, 10
RDW and MPV might become easy to use follow-
up markers in patients with CKD, but what kind of risk 
should we attribute to CKD patients first, when we take 
these hematological parameters into account? Possible 
alternatives are; accelerated progression of CKD, in-
creased probability of cardiovascular events, and emerg-
ing of a condition called malnutrition-inflammation 
syndrome. The relations concerning these hematological 
parameters and adverse outcomes in patients with CKD 
are thought to be associated with chronic inflammation, 
oxidative stress, and malnutrition. Yet, the exact causal 
link or the order of importance is not solved.
In the absence of systemic inflammation, RDW 
could be a marker for the differential diagnosis of micro-
cytic anemia. However, in patients with advanced CKD, 
there is more to it than that because RDW seems to be 
a marker of inflammatory and nutritional status in this 
population.13, 14 High RDW was found to be associated 
with all-cause and cardiovascular mortality in CKD 
patients after adjusting for hemoglobin levels.1, 12, 14
A study by Lu et al. revealed a result that the ef-
fect of RDW on CVD was independent of hemoglobin 
and also creatinine levels in stage 1-5 CKD patients.4 
Interestingly, in the fully adjusted model of our study, 
RDW was not associated with CVD along with eGFR, 
but it was associated with the comorbidity score, CRP, 
albumin, and hemoglobin values. As in our patients, 
when CKD has already progressed to advanced stages, 
adverse conditions such as systemic inflammation, 
comorbidity burden and renal anemia increase the risk 
for CVD and all-cause mortality.15, 16 We think that high 
RDW could be the reflection of this cumulative trend 
Table 1. Demographics, clinical features, and labora-
tory values within the study population
Variable CKD patients (n = 627)
Age, years 63.18 ± 14.94
Gender, M/F; n (%) 366 (58.4)/261 (41.6)
Body mass index, kg/m2 26.23 ± 4.48
CKD stage 3/4/5; n (%) 280 (44.6)/172 (27.4)/175 (28.0)
eGFR, mL/min/1.73 m2 27.36 ± 1.51
DM; n (%) 291 (46.4)
CVD; n (%) 242 (38.6)
Hypertension; n (%) 505 (80.5)
RDW mean/median, % 14.79 ± 1.99/14.50
High RDW; n (%) 303 (48.3)
MPV mean/median, fl 9.73 ± 1.55/9.90
Low MPV, n (%) 311 (49.6)
CCI score 5.83 ± 2.6
Haemoglobin, g/dL 12.02 ± 2.21
Platelet count, X103/mm3 238.49 ± 79.20
Creatinine, mg/dL 3.23 ± 2.21
CRP, mg/L 19.08 ± 27.96
Albumin, g/dL 3.89 ± 0.54
Ca × P product, mg2/dL2 35.82 ± 10.46
SBP, mmHg 139.83 ± 27.96
Data presentation; mean ± SD. CCI, Charlson Comorbidity 
Index; CKD, chronic kidney disease; CRP, C-reactive protein; 
CVD, cardiovascular disease; DM, diabetes mellitus; eGFR, 
estimated glomerular filtration rate; F, female; M, male; MPV, 
mean platelet volume; P, phosphorus; RDW, red cell distribution 
width; SBP, systolic blood pressure.
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encircled around inflammatory stress in patients with 
advanced CKD. In another study by Yonemoto et al. 
CKD patients with high RDW were older with higher 
prevalence of prior CVD, higher CRP levels, lower 
eGFR, albumin and hemoglobin levels.3 In addition 
to their results, our CKD patients with high RDW had 
higher prevalence of DM along with higher comorbidity 
scores, and male gender predominancy.
Studies comparing CKD patients with healthy 
individuals have revealed larger platelet volumes in 
patients with CKD.5, 10 Thus, large and reactive platelets 
might contribute to the increased incidence of vascular 
disease. In fact, some studies have demonstrated a rela-
tion between increased platelet size and CVD in CKD 
patients.10, 17 On the other hand, as CKD progresses to 
end stage renal disease (ESRD), the presence of uremic 
toxins may lead to a qualitative decrease in platelet 
functions.2 Therefore, we might assume that the size 
Table 3. Univariate associates of RDW and MPV in CKD patients
RDW MPV
Variable r P r P
Age 0.172 < 0.001 –0.035 0.386
eGFR –0.171 < 0.001 0.147 < 0.001
CCI 0.230 < 0.001 –0.024 0.552
Hemoglobin –0.329 < 0.001 0.102 0.010
Platelet count –0.077 0.054 –0.127 0.001
Creatinine 0.122 0.002 –0.144 < 0.001
CRP 0.359 < 0.001 –0.116 0.004
Albumin –0.308 < 0.001 0.080 0.046
Ca × P product 0.054 0.180 –0.044 0.271
SBP 0.042 0.321 –0.050 0.243
CCI, Charlson Comorbidity Index; CKD, chronic kidney disease; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; 
MPV, mean platelet volume; P, phosphorus; RDW, red cell distribution width; SBP, systolic blood pressure.
Table 2. Patient characteristics according to median RDW and median MPV values
Variable RDW ≤ 14.50%  
(n = 324)
RDW > 14.50%  
(n = 303)
P value MPV ≥ 9.90 fl  
(n = 316)
MPV < 9.90 fl  
(n = 311)
P value
Age, years 61.13 ± 14.94 65.38 ± 14.64 < 0.001 62.02 ± 14.64 64.36 ± 15.19 0.050
Male, n/(%) 210/(64.8) 156/(51.4) 0.001 177/(56.0) 189/(60.7) 0.227
eGFR, mL/min 29.95 ± 15.79 24.59 ± 14.74 < 0.001 28.85 ± 15.33 25.85 ± 15.58 0.015
DM, n (%) 129/39.8 162/53.4 0.001 154/48.7 137/44.0 0.240
CVD, n (%) 97/29.9 145/47.8 < 0.001 127/40.1 115/36.9 0.409
HT, n (%) 254/78.4 251/82.8 0.160 253/80.0 252/81.0 0.760
CCI 5.43 ± 2.03 6.26 ± 1.99 < 0.001 5.76 ± 2.01 5.90 ± 2.10 0.414
Hemoglobin 12.6 ± 2.14 11.30 ± 2.06 < 0.001 12.19 ± 2.20 11.85 ± 2.21 0.61
Platelets 241.53 ± 68.36 235.25 ± 89.34 0.326 231.00 ± 78.16 246.10 ± 79.64 0.017
Creatinine 3.01 ± 2.16 3.47 ± 2.25 0.009 2.98 ± 2.01 3.49 ± 2.38 0.004
CRP 14.47 ± 24.40 24.02 ± 30.59 < 0.001 17.72 ± 28.04 20.47 ± 27.85 0.218
Albumin 4.01 ± 0.46 3.76 ± 0.57 < 0.001 3.92 ± 0.52 3.86 ± 0.54 0.165
Ca × P 35.17 ± 10.19 36.52 ± 10.72 0.108 35.43 ± 9.99 36.22 ± 10.93 0.344
SBP, mmHg 139.15 ± 27.04 140.56 ± 27.50 0.545 138.07 ± 25.91 141.71 ± 28.54 0.118
Data presentation; mean ± SD. CCI, Charlson Comorbidity Index; CRP, C-reactive protein; CVD, cardiovascular disease; DM, diabetes 
mellitus; eGFR, estimated glomerular filtration rate; HT, hypertension; MPV, mean platelet volume; P, phosphorus; RDW, red cell 
distribution width; SBP, systolic blood pressure.
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and reactivity of the platelets in patients with CKD 
might differ according to the CKD stage and inflamma-
tory status.
High MPV was also found to be associated with 
worse renal function in patients with pre-dialytic stages 
of CKD, and higher extent of coronary disease in 
patients with ESRD.2, 5, 18 However, some studies have 
reported decreased MPV values, particularly in patients 
with ESRD.2, 19 In our study, stage 3-5 CKD patients 
with lower MPV had lower mean eGFR and, MPV was 
inversely correlated with serum CRP levels. On top 
of that, our fully-adjusted regression model supported 
the positive correlation between MPV and eGFR. We 
would like to interpret our results as the reflection of 
systemic inflammation and uremic state in our patients 
with advanced CKD.
This study reached a satisfactory sample size 
even though we used extensive exclusion criteria. 
Nevertheless, there were some limitations to it. The 
cross-sectional design of our study seems to be its’ main 
limitation. DM is a condition that may affect RDW 
values, but it is the most common etiology for CKD. 
Therefore, instead of excluding CKD patients with DM 
we tried to determine its’ effects in a regression model 
along with other comorbidities. The presence of other 
possible confounders that we were not able to take into 
account, such as vitamin B12 and folic acid levels of the 
patients and the use of the medications like ticlopidine 
and clopidogrel could be another limitation. The use of 
erythrocyte stimulating agents is also a limitation that 
may affect the RDW results, but most of the patients 
with advanced CKD receive these medications at ane-
mic intervals.
In conclusion, high RDW was associated with 
many clinical features including worse renal function, 
older age, male gender, DM, CVD, comorbidity score, 
anemia, and increased CRP levels in patients with 
advanced CKD in this study. However, after controlling 
for multiple confounders, our regression model revealed 
that higher RDW levels could more likely be the reflec-
tion of comorbidity burden, anemia, and inflammatory 
status of the CKD patients. Meanwhile, CKD patients 
with low MPV had a worse renal function, and higher 
platelet counts. Low MPV was still associated with low 
eGFR after controlling for multiple confounders. We 
think that patients with advanced CKD, especially those 
who have ESRD along with high comorbidity burden 
and chronic inflammation might have low instead of 
normal or high MPV values. MPV also showed correla-
tions with CRP and albumin levels, but our data was not 
enough to deduce an important relation.
Patients with advanced CKD are in an inflammato-
ry state due to increased cytokine production, oxidative 
stress, vitamin D deficiency, malnutrition, and suscepti-
bility to infections. This inflammatory state contributes 
to problems like atherosclerosis, vascular calcification, 
anemia, sarcopenia, and progression of CKD itself. 
Hematological parameters like RDW and MPV seem 
to be affected by not one, but a combination of some 
of these unappealing conditions. Therefore, RDW and 
MPV could be promising parameters to indicate CKD 
patients with a higher probability to reach the adverse 
outcomes that are related to systemic inflammation.
The authors declare no conflict of interest.
Fig. 1. Comparison of RDW and MPV values of the patients 
according to CKD stages. RDW was higher in stage 5 CKD 
patients compared to stage 3 CKD patients. MPV was lower in 
stage 5 CKD patients compared to stage 3 and stage 4 CKD pa-
tients. CKD, chronic kidney disease; MPV, mean platelet volume; 
RDW, red cell distribution width.
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